BRIO

Visus Therapeutics Presents Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia at Eyecelerator @ ASCRS 2023

Retrieved on: 
Thursday, May 4, 2023
Professional Services, Health, Venture Capital, Clinical Trials, Optical, Biotechnology, Eye, Food and Drug Administration, Presbyopia, BRIO, FDA, Therapy, Visual acuity, Carbachol, Food, Safety, Visu, Pharmaceutical industry, EU

Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today presented key topline data from the pivotal Phase 3 BRIO-I clinical trial.

Key Points: 
  • Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today presented key topline data from the pivotal Phase 3 BRIO-I clinical trial.
  • The study evaluating the safety and efficacy of BRIMOCHOL™ PF, a preservative-free ophthalmic solution for the treatment of presbyopia, met its primary and secondary endpoints.
  • “With the completion of our BRIO-I study and positive Phase 3 data in hand, we see a clear pathway forward,” said Ben Bergo, co-founder, and chief executive officer at Visus Therapeutics.
  • Following the read-out of the vehicle-controlled BRIO-II, it is the Company’s current expectation to file a New Drug Application (NDA) with the US FDA in 2H 2024.

Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF™ for the Treatment of Presbyopia

Retrieved on: 
Thursday, April 20, 2023
Research, Venture Capital, Clinical Trials, Professional Services, Other Health, Biotechnology, Pharmaceutical, Health, Optical, Science, Refractive surgery, NCT, Eye, Presbyopia, Sudden Strike 3: Arms for Victory, ASCRS, Element, BRIO, EMA, American Society of Cataract and Refractive Surgery, Patient, Annual general meeting, Cataract, Therapy, Society, Pharmaceutical industry, Brimonidine, Carbachol

BRIMOCHOL PF demonstrated highly statistically significant improvements in near and distance binocular visual acuity at multiple timepoints over carbachol and brimonidine.

Key Points: 
  • BRIMOCHOL PF demonstrated highly statistically significant improvements in near and distance binocular visual acuity at multiple timepoints over carbachol and brimonidine.
  • “Visus Therapeutics is the first and only company to demonstrate contribution-of-elements in a presbyopia pivotal study.
  • “BRIMOCHOL PF was well-tolerated in a broad presbyopia population with no study subjects discontinuing due to adverse events.
  • If approved, BRIMOCHOL PF has the potential to last a full workday in presbyopia patients not fully served at this time.”

Visus Therapeutics Completes Enrollment in BRIO-I, a Phase 3 Clinical Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia

Retrieved on: 
Wednesday, March 22, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Retina, Therapy, Smartphone, Eye, Presbyopia, BRIO, Reading, FDA, PF, Carbachol, Safety, Visu, Pupil, Pharmaceutical industry, Q2

“We are thrilled to have reached this milestone in the BRIO-I study, as part of our Phase 3 program,” said Ben Bergo, co-founder and chief executive officer of Visus Therapeutics.

Key Points: 
  • “We are thrilled to have reached this milestone in the BRIO-I study, as part of our Phase 3 program,” said Ben Bergo, co-founder and chief executive officer of Visus Therapeutics.
  • “BRIMOCHOL PF has the potential to be a highly appealing presbyopia correcting eye drop, providing both the duration and tolerability profile presbyopes desire.
  • This allows only the light rays focused on the retina to enter the eye, thereby sharpening vision.
  • “By demonstrating this so-called contribution-of-elements in this study, Visus would become the first company to meet this FDA-required high bar for approving a combination product for presbyopia in a pivotal phase 3 study.

CPUC Program Launches To Innovate Energy Efficiency Through Market Transformation

Retrieved on: 
Tuesday, January 31, 2023
Woman, California Public Utilities Commission, Public utilities commission, Eye, San Francisco Bay Area, European Space Resources Innovation Centre, CPUC, Partner, SAN, Multimedia, Environment, Public utility, Renewable energy, BRIO

SAN FRANCISCO, Jan. 31, 2023 /PRNewswire/ -- The California Public Utilities Commission (CPUC) today announced the state's first-ever Market Transformation Administrator (CalMTA) to advance groundbreaking energy efficiency transformation initiatives that will bring sustainable, cost-effective market changes to California.

Key Points: 
  • SAN FRANCISCO, Jan. 31, 2023 /PRNewswire/ -- The California Public Utilities Commission (CPUC) today announced the state's first-ever Market Transformation Administrator (CalMTA) to advance groundbreaking energy efficiency transformation initiatives that will bring sustainable, cost-effective market changes to California.
  • "Key elements adopted in the market transformation framework are from contributions of the California Energy Efficiency Coordinating Committee."
  • Market transformation is an effective method in various technology areas within the energy sector, including energy efficiency, which aims to eliminate market barriers to adoption of innovative technologies in support of California's clean energy and climate goals.
  • Market transformation initiatives strive to be self-sustaining and can yield measurable benefits that remain long after active market interventions have ended.

RAVENSBURGER AG EXPANDS EXECUTIVE BENCH STRENGTH - FILIP FRANCKE TO DRIVE WORLDWIDE EXPANSION AS GLOBAL HEAD OF GAMES, STEPHANE MADI APPOINTED CEO OF RAVENSBURGER NORTH AMERICA

Retrieved on: 
Tuesday, January 10, 2023
ThinkFun, Head, Acquisition, Growth, Mega Brands, TCG, Toy, Ravensburger, BRIO, Francke

PORTSMOUTH, N.H., Jan. 10, 2023 /PRNewswire/ -- Ravensburger AG, one of the world's leading makers of toys, puzzles, and games, today announced an expansion to their executive structure. Filip Francke will lead the company's rapidly growing gaming division as Global Head of Games. His role within Ravensburger AG will expand to focus on all the company's gaming ventures, including the company's highly anticipated entry into the billion-dollar trading card game (TCG) market later this year with Disney Lorcana. Concurrently, Stephane Madi, formerly Head of Ravensburger Canada, has been named as CEO of Ravensburger North America, where he will oversee the company's portfolio and operations in the United States and Canada.

Key Points: 
  • Filip Francke will lead the company's rapidly growing gaming division as Global Head of Games.
  • Concurrently, Stephane Madi, formerly Head of Ravensburger Canada, has been named as CEO of Ravensburger North America, where he will oversee the company's portfolio and operations in the United States and Canada.
  • Francke has served as CEO of Ravensburger North America since joining the company in 2017 from Helly Hansen and added the title of Global Head of Games in 2019.
  • In his new role, Madi will oversee Ravensburger AG's portfolio of brands in the United States and Canada, including Ravensburger, BRIO, ThinkFun and Wonder Forge.

Volvo CE partners with BRIO to inspire budding engineers

Retrieved on: 
Monday, September 5, 2022
Partnership, Safety, Ageing, Engineering, Autumn, Builder, Lifting, Volvo Museum, Volvo, Volvo Construction Equipment, BRIO AB, BRIO, Eskilstuna, Product design, Haulage, CE, FSC, Life, Heavy equipment, Toy

GOTHENBURG, Sweden, Sept. 5, 2022 /PRNewswire/ -- BRIO Builder's newest range is a construction system featuring a wheel loader, hauler, and excavator, designed in close collaboration with Volvo CE to ensure they closely resemble their real-life counterparts, and all proudly sporting the iconic yellow livery of Volvo CE.

Key Points: 
  • Volvo Construction Equipment (Volvo CE) and family favorite BRIO AB are joining forces.
  • GOTHENBURG, Sweden, Sept. 5, 2022 /PRNewswire/ -- BRIO Builder's newest range is a construction system featuring a wheel loader, hauler, and excavator, designed in close collaboration with Volvo CE to ensure they closely resemble their real-life counterparts, and all proudly sporting the iconic yellow livery of Volvo CE.
  • Arvid Rinaldo, Brand Partnership at Volvo CE, says: "We're thrilled to see this partnership with BRIO come to life.
  • Thanks to a close relationship between teams across the two brands, the BRIO models have been thoughtfully created to align with Volvo CE's brand identity."

Volvo CE partners with BRIO to inspire budding engineers

Retrieved on: 
Monday, September 5, 2022
Partnership, Safety, Ageing, Engineering, Autumn, Builder, Lifting, Volvo Museum, Volvo, Volvo Construction Equipment, BRIO AB, BRIO, Eskilstuna, Product design, Haulage, CE, FSC, Life, Heavy equipment, Toy

GOTHENBURG, Sweden, Sept. 5, 2022 /PRNewswire/ -- BRIO Builder's newest range is a construction system featuring a wheel loader, hauler, and excavator, designed in close collaboration with Volvo CE to ensure they closely resemble their real-life counterparts, and all proudly sporting the iconic yellow livery of Volvo CE.

Key Points: 
  • Volvo Construction Equipment (Volvo CE) and family favorite BRIO AB are joining forces.
  • GOTHENBURG, Sweden, Sept. 5, 2022 /PRNewswire/ -- BRIO Builder's newest range is a construction system featuring a wheel loader, hauler, and excavator, designed in close collaboration with Volvo CE to ensure they closely resemble their real-life counterparts, and all proudly sporting the iconic yellow livery of Volvo CE.
  • Arvid Rinaldo, Brand Partnership at Volvo CE, says: "We're thrilled to see this partnership with BRIO come to life.
  • Thanks to a close relationship between teams across the two brands, the BRIO models have been thoughtfully created to align with Volvo CE's brand identity."

Integrative Cancer Expert - Dr. Nathan Goodyear

Retrieved on: 
Tuesday, April 12, 2022
Wellness, Insulin potentiation therapy, Hormone, University, Louisiana Tech University, Self-signed certificate, Hyperthermia, BRIO, LSU Health Sciences Center Shreveport, Patient, Genetics, Board, Education, Regenerative medicine, Lyme disease, Cancer, Medicine, Medical director, Malnutrition, MD, Immune system, Vitamin, Gynaecology, MDH, Bachelor of Arts in Clinical Psychology, Hope, Alternative medicine, Science, Chief resident, Toxicity, Medical device, Obstetrics

SCOTTSDALE, Ariz., April 12, 2022 /PRNewswire/ -- BRIO-MEDICAL is pleased to announce the appointment of Dr. Nathan Goodyear, MD, MDH, ABAARM as Medical Director.

Key Points: 
  • SCOTTSDALE, Ariz., April 12, 2022 /PRNewswire/ -- BRIO-MEDICAL is pleased to announce the appointment of Dr. Nathan Goodyear, MD, MDH, ABAARM as Medical Director.
  • "As a pioneer in the use of Insulin Potentiation Therapy, High Dose Vitamin C, and Hyperthermia for the integrative treatment of cancer, we are so excited that Dr. Goodyear has come to lead our medical team," said Rusty Roberts, President of Brio-Medical."
  • Practicing Integrative Medicine since 2006, Dr. Goodyear is a Fellow in Functional and Regenerative Medicine and is licensed by the Arizona Homeopathic and Integrative Medical Board in the State of Arizona.
  • About Brio-Medical: Established in 2019 in Scottsdale, Arizona, Brio-Medical is an integrative alternative cancer treatment center and immune recovery facility offering advanced, research-based integrative medical treatments for all types of cancer, Lyme Disease, and chronic illnesses.

CAMP Introduces First Disney Themed Experience - Mickey & Friends: An Extra Big Adventure

Retrieved on: 
Tuesday, April 5, 2022
Jewellery, Disney Vacation Club, Mickey au Camp de Gurs, Publishing, NEW, Sale, Growth, Multimedia, D23, Friends, The Magic Door, CAMP, Magic, The Clark Family Experience, Program, CEO, A Barefoot Dream, Fifth Avenue, Summer, History, Amusement park, BRIO, The Walt Disney Company

NEW YORK, April 5, 2022 /PRNewswire/ -- CAMP, the Family Experience Company, will open its Magic Door to its newest themed experience: "Mickey & Friends x CAMP: An Extra Big Adventure" on May 28th at the 5th Avenue flagship store located at 110 5th Avenue in New York City. This interactive, larger-than-life collaboration is the first of several Disney-themed experiences that CAMP will launch in 2022 and that will travel to other CAMP locations later this year and beyond.

Key Points: 
  • CAMP recently participated in the 2021 Disney Accelerator, a program that is designed to accelerate the growth of innovative companies from around the world.
  • Behind CAMP's signature Magic Door is an immersive experience where families will be guided by a CAMP Counselor through a narrative-driven adventure, packed with plenty of Disney and CAMP magic.
  • With plenty of interactive entertainment and numerous photo opportunities, the experience will be unforgettable family fun, the way only Disney and CAMP could provide.
  • "By collaborating with CAMP, we are able to connect families with our characters like Mickey & Friends through innovative storytelling and an immersive retail experience."

Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL™ PF for the Treatment of Presbyopia

Retrieved on: 
Tuesday, March 22, 2022
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Pupil, Therapy, LinkedIn, Smartphone, BRIO, Glaucoma, Research, Wound healing, Reading, Brimonidine, Retina, Carbachol, Prevalence, American Academy of Optometry, Safety, Reduction, Presbyopia, Time, Ageing, Clinical study design, American Academy, Hardship, Visu, McLaurin, Eye, Instagram, Insurance, Patient, Pharmaceutical industry, Telescopic sight, Optometry, New Drug Application, Twitter, PRESBYOPIA, VISUS THERAPEUTICS

The initiation of the BRIO trials follows compelling topline data from the companys Phase 2 VIVID clinical study, which demonstrated two preservative-free formulations, BRIMOCHOL PF and Carbachol PF, were well tolerated and met clinical outcomes to support advancement into pivotal trials.

Key Points: 
  • The initiation of the BRIO trials follows compelling topline data from the companys Phase 2 VIVID clinical study, which demonstrated two preservative-free formulations, BRIMOCHOL PF and Carbachol PF, were well tolerated and met clinical outcomes to support advancement into pivotal trials.
  • The initiation of our first Phase 3 trial is a momentous occasion for Visus Therapeutics.
  • The BRIO-I and BRIO-II trials are designed to study BRIMOCHOL PF, a novel, fixed-dose combination of carbachol and brimonidine tartrate, and a proprietary, preservative-free formulation of carbachol monotherapy.
  • In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic drug candidates with applications in corneal wound healing, glaucoma and age-related macular degeneration.